retatrutide phase 3 trial results for have been released, and the data are generating a lot of discussion in obesity medicine. TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and followed participants for Interesting data from the @EliLillyandCo

Our Research Lead examined anonymized platform data from: 5,864 US adults using tirzepatide (Mounjaro or Zepbound) 4,456 US adults using semaglutide (Ozempic or Wegovy) Inclusion criteria: Active GLP-1 therapy with weekly injections Minimum 12-week tracking duration Adherence threshold: 1 injection log and 1 weight entry per week No weight entries outside physiological bounds (30300 kg) or with weekly changes exceeding 5% Primary outcome: Percentage body weight change from baseline, calculated as [(current weight baseline weight) / baseline weight] 100 , where negative values indicate weight loss Data collection period: Data were collected from all available platform records through January 2026, representing naturalistic use patterns without researcher intervention

The evidence is promising, but its not a TikTok miracle

Additionally, bidirectional and multiple MR approaches were employed to explore the causal relationship between T2D and SA, complemented by sensitivity analyses, enhancing the robustness of the results

If youve been denied coverage or are navigating treatment without insurance, help is available

Both over-the-counter and prescription medicines can treat constipation

10.1161/CIRCRESAHA.117.311586 83 KalraS